Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian surveyAlice Indini, Francesco Grossi, Livio Blasi et al.|European Journal of Cancer|2020Cited by 111
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access programEditta Baldini, Diana Giannarelli, Alice Lunghi et al.|Lung Cancer|2019Cited by 42
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative studyPaolo A. Ascierto, Claudia Trojaniello, Eleonora Cioli et al.|Frontiers in Oncology|2023Cited by 3
Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.Paolo A. Ascierto, Vanna Chiarion‐Sileni, Pietro Quaglino et al.|Journal of Clinical Oncology|2024Cited by 2
Immune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programmeE.H. Baldini, Diana Giannarelli, Alessandro Lunghi et al.|Annals of Oncology|2018Cited by 1